Compare · MBRX vs SBFM
MBRX vs SBFM
Side-by-side comparison of Moleculin Biotech Inc. (MBRX) and Sunshine Biopharma Inc. (SBFM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MBRX and SBFM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MBRX is the larger of the two at $8.3M, about 3.7x SBFM ($2.2M).
- MBRX has been more active in the news (15 items in the past 4 weeks vs 5 for SBFM).
- MBRX has more recent analyst coverage (3 ratings vs 0 for SBFM).
- Company
- Moleculin Biotech Inc.
- Sunshine Biopharma Inc.
- Price
- -
- -
- Market cap
- $8.3M
- $2.2M
- 1M return
- +8.65%
- -
- 1Y return
- -96.12%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 15
- 5
- Recent ratings
- 3
- 0
Moleculin Biotech Inc.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Sunshine Biopharma Inc.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Latest MBRX
- Amendment: SEC Form SCHEDULE 13G/A filed by Moleculin Biotech Inc.
- Moleculin Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
- SEC Form 10-Q filed by Moleculin Biotech Inc.
- Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Moleculin Secures Australian Patent for Annamycin Formulation Technology
- Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
- Chief Science Officer Picker Donald H converted options into 17 shares and covered exercise/tax liability with 4 shares, increasing direct ownership by 0.15% to 8,718 units (SEC Form 4)
- Chief Financial Officer Foster Jonathan P. converted options into 41 shares and covered exercise/tax liability with 10 shares, increasing direct ownership by 0.15% to 20,291 units (SEC Form 4)
Latest SBFM
- SEC Form DEFA14A filed by Sunshine Biopharma Inc.
- SEC Form 10-Q filed by Sunshine Biopharma Inc.
- SEC Form DEF 14A filed by Sunshine Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sunshine Biopharma Inc.
- SEC Form DEF 14C filed by Sunshine Biopharma Inc.
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
- SEC Form PRE 14C filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.
- SEC Form 424B4 filed by Sunshine Biopharma Inc.